Dr. Jeffrey Stolwijk | Scientific Director
Uneedle

Jeffrey Stolwijk is a cell biologist and toxicologist with deep expertise in oncology, immunology, and translational science. As Scientific Director at Uneedle, he plays a central role in advancing clinical programs in collaboration with Uneedle's pharmaceutical and biotech partners. His work focuses on enabling more effective intradermal delivery of oncology and vaccine therapies using Uneedle's proprietary microneedle platform—an innovation aimed at improving targeting of dendritic cells, increasing immunogenicity, and reducing the need for high-dose systemic treatments.
With over a decade of experience spanning academic research and industry, Jeffrey has led and supported numerous preclinical and early clinical-stage programs in cancer immunotherapy. His background in assay development, microscopy, flow cytometry, and immune cell biology underpins his ability to translate complex scientific concepts into practical, clinically relevant solutions. Passionate about improving patient outcomes in oncology, he is committed to helping partners accelerate the development of next-generation cancer treatments.